CCL Oct 2014 - The Cancer Letter

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Request Cancellation

Renew today!

Your subscription has lapsed. Subscribe today to access this content.

SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.

LOGIN SUBSCRIBE NOW

SEARCH DATE

SEARCH TEXT

Cancel

OK

Cancel

OK

Delete Account

Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below

Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial

Cobimetinib-Zelboraf Therapy Increases OS In BRAF V600 Mutation-Positive Disease

Study: Angiopoietin-2 Levels May Predict Lenvatinib Response

Afatinib Delays Tumor Growth in LUX-Head and Neck 1 Study

Zytiga and Prednisone Extends Overall Survival in mCRPC Trial

Anamorelin Increases Body Mass in Two Global Phase III Trials

NCI CTEP-Approved Trials for the Month of October

FDA Approves Velcade Injection In Mantle Cell Lymphoma

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login